CAMBRIDGE, U.K., May 23, 2005 (PRIMEZONE) -- Astex:
-- Astex announces first CTA for novel cancer drug -- AT7519 went from first synthesis to CTA approval in just 14 months -- less than half the industry average -- Signifies transition from platform to product company
Full press release attached below: http://hugin.info/132636/R/995337/150883.pdf